Company Filing History:
Years Active: 2025
Title: The Innovative Contributions of Anna Friis
Introduction
Anna Friis is a notable inventor based in Uppsala, Sweden. She has made significant strides in the field of neurotoxin formulations, contributing to advancements in therapeutic applications. Her work focuses on creating stable liquid formulations that are free of animal proteins, which is a crucial aspect in modern medicine.
Latest Patents
Anna Friis holds a patent for a liquid neurotoxin formulation stabilized with tryptophan or tyrosine. This invention relates to stable liquid neurotoxin formulations that comprise a surfactant, an amino acid selected from tryptophan and tyrosine, and a buffer containing sodium, chloride, and phosphate ions. The formulations have a pH between 5.5 and 8 and are stable for two months. These compositions are particularly suitable for therapeutic use, allowing for administration to patients to achieve desired therapeutic or aesthetic effects. The invention also highlights the use of tryptophan and tyrosine to protect proteinaceous neurotoxins from degradation in liquid compositions that are free of animal-derived proteins.
Career Highlights
Throughout her career, Anna has worked with prominent companies in the pharmaceutical industry. Notable among these are Ipsen Biopharm Limited and Galderma Holding SA. Her experience in these organizations has allowed her to refine her expertise in neurotoxin formulations and contribute to innovative solutions in the field.
Collaborations
Anna has collaborated with esteemed colleagues, including Anders Jarstad and Ulf Stahl. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Anna Friis is a pioneering inventor whose work in neurotoxin formulations has the potential to impact therapeutic practices significantly. Her contributions reflect a commitment to advancing medical science through innovative solutions.